North Carolina Headlines

DelveInsight’s, “Cocaine Use Disorder Pipeline Insight, 2025,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Cocaine Use Disorder pipeline landscape. It covers the Cocaine Use Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cocaine Use Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Cocaine Use Disorder Research. Learn more about our innovative pipeline today! @ Cocaine Use Disorder Pipeline Outlook

Key Takeaways from the Cocaine Use Disorder Pipeline Report

• In May 2025, University of Massachusetts, Worcester announced a study is a 4-site, 12-week, novel, feasibility, investigation of patients who have co-occurring diagnoses of schizophrenia and current substance use disorder (alcohol, cocaine, heroin, or cannabis). Thirty-nine participants will be randomly assigned to switch to brexpiprazole (the brexpiprazole group) or remain on the same antipsychotic treatment (the control group). The study will be conducted at 4 sites in the US. The investigators expect to enroll 80 subjects across 3 sites. UMass Medical School, Worcester MA is the lead site. Sub-sites include Massachusetts General Hospital (MGH) and the University of North Carolina at Chapel Hill (UNC).
• DelveInsight’s Cocaine Use Disorder pipeline report depicts a robust space with 12+ active players working to develop 12+ pipeline therapies for Cocaine Use Disorder treatment.
• The leading Cocaine Use Disorder Companies such as Embera NeuroTherapeutics, Novartis, Omeros Corporation, Indivior, Saniona, KemPharm, Kinoxis Therapeutics, Camino Pharma, EryDel, Astraea Therapeutics and others.
• Promising Cocaine Use Disorder Pipeline Therapies such as Quetiapine, Risperidone, Brexpiprazole, quetiapine, Buprenorphine + Naltrexone, TNX-1300 (Injection), AFQ056, NS2359 and others.

Stay informed about the cutting-edge advancements in Cocaine Use Disorder Treatments. Download for updates and be a part of the revolution in care @ Cocaine Use Disorder Clinical Trials Assessment

Cocaine Use Disorder Emerging Drugs Profile

• EMB-001: Embera NeuroTherapeutics

EMB-001 is a patented combination product comprising two FDA-approved medications, the cortisol synthesis inhibitor metyrapone and the benzodiazepine oxazepam. The innovation is based on insights into the physiologic responses to stress in addiction. EMB-001 is thought to act by mechanisms distinct from those of existing addiction treatments and is hypothesized to reduce the increased activity in the stress response system induced by drugs, cues and stressors that contribute to relapse in addiction. Currently, it is in Phase II stage of clinical trial evaluation to treat Cocaine Use Disorder.

• NS2359: Saniona

NS2359 is a triple reuptake inhibitor, which blocks the reuptake of dopamine, norepinephrine, and serotonin in a similar manner to cocaine. However, NS2359 dissociates slowly from these transporters and has a long human half-life (up to 10 days) which makes frequent dosing unnecessary. NS2359s pharmacological profile means that it may be able to reduce cocaine withdrawal symptoms, reduce cocaine craving and reduce cocaine-induced euphoria. In preclinical trials, NS2359 has been shown to reduce the reinforcing effects of cocaine and may have effects on cue induced drug craving. Furthermore, human trials with NS2359 have shown that NS2359 has little abuse potential and does not have adverse interactions with cocaine. Thus, NS2359 is a very promising medication for the treatment of cocaine dependence. A Phase II clinical trial evaluating NS2359 has been completed for the treatment of Cocaine Dependence.

• KNX100: Kinoxis Theraputics

Kinoxis’ lead candidate (KNX100) is being developed for the mitigation of opioid withdrawal symptoms. KNX100 has a novel, undisclosed mechanism of action and is nearing Phase I clinical trials. The company is also exploring other indications for its lead compound, KNX100, as promising preclinical results have been achieved in animal models of cocaine, methamphetamine, nicotine, and alcohol use disorders, as well as models of agitation and aggression.

The Cocaine Use Disorder Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Cocaine Use Disorder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cocaine Use Disorder Treatment.
• Cocaine Use Disorder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Cocaine Use Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cocaine Use Disorder market

Explore groundbreaking therapies and clinical trials in the Cocaine Use Disorder Pipeline. Access DelveInsight’s detailed report now! @ New Cocaine Use Disorder Drugs

Cocaine Use Disorder Companies

Embera NeuroTherapeutics, Novartis, Omeros Corporation, Indivior, Saniona, KemPharm, Kinoxis Therapeutics, Camino Pharma, EryDel, Astraea Therapeutics and others.

Cocaine Use Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Molecule Type

Cocaine Use Disorder Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Download DelveInsight’s latest report to gain strategic insights into upcoming therapies and key developments @ Cocaine Use Disorder Market Drivers and Barriers, and Future Perspectives

Scope of the Cocaine Use Disorder Pipeline Report

• Coverage- Global
• Cocaine Use Disorder Companies- Embera NeuroTherapeutics, Novartis, Omeros Corporation, Indivior, Saniona, KemPharm, Kinoxis Therapeutics, Camino Pharma, EryDel, Astraea Therapeutics and others.
• Cocaine Use Disorder Pipeline Therapies- Quetiapine, Risperidone, Brexpiprazole, quetiapine, Buprenorphine + Naltrexone, TNX-1300 (Injection), AFQ056, NS2359 and others.
• Cocaine Use Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Cocaine Use Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Cocaine Use Disorder drug development? Find out in DelveInsight’s exclusive Cocaine Use Disorder Pipeline Report—access it now! @ Cocaine Use Disorder Emerging Drugs and Major Companies

Table of Contents

1. Executive Summary
2. Cocaine Use Disorder: Overview
3. Pipeline Therapeutics
4. Therapeutic Assessment
5. Cocaine Use Disorder – DelveInsight’s Analytical Perspective
6. Mid Stage Products (Phase II)
7. EMB-001: Embera NeuroTherapeutics
8. Drug profiles in the detailed report…..
9. Early Stage Products (Phase I)
10. OMS527: Omeros Corporation
11. Drug profiles in the detailed report…..
12. Preclinical and Discovery Stage Products
13. AT-312: Astraea Therapeutics
14. Inactive Products
15. Cocaine Use Disorder Key Companies
16. Cocaine Use Disorder Key Products
17. Cocaine Use Disorder- Unmet Needs
18. Cocaine Use Disorder- Market Drivers and Barriers
19. Cocaine Use Disorder- Future Perspectives and Conclusion
20. Cocaine Use Disorder Analyst Views
21. Cocaine Use Disorder Key Companies
22. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cocaine-use-disorder-pipeline-insight